Free Submission Public Relations &
Deutsch English


PharmaPoint: Seasonal Influenza Vaccines Japan Drug Forecast and Market Analysis - New Study Released

Print article Print article
2013-01-21 15:33:19 - New Pharmaceuticals research report from GlobalData is now available from Fast Market Research

GlobalData has released its new Country report, "PharmaPoint: Seasonal Influenza Vaccines Japan Drug Forecast and Market Analysis". Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers

that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

Full Report Details at
- ..

The Japanese influenza vaccine market is valued at approximately $702 million in 2012. The projected drivers for growth of the Japanese influenza vaccine market include the entrance of large, multinational firms into the marketplace, a government commitment to educating the populace about the importance of preventative medicine (including vaccination), and growth of the elderly population. GlobalData does not project that intradermal and intranasal vaccines will enter the Japan market during the forecast period, leaving all market dynamics between existing and new intramuscular vaccines.

The Japanese influenza vaccine market differs from its US or European counter parts due the large role that non-commercial entities play in the marketplace. For example, the Chemo-Sero-Therapeutic Research Institute is the market leader. The organization is also referred to as Kaketsuken (abbreviation of its name in Japanese). Kaketsuken's recent completion of a new influenza vaccine plant, which doubled its production capacity, is an embodiment of the resources and commitment to the influenza vaccines that have enabled it to attain its position in the Japanese market.


* Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for the top drugs in Japan from 2012 to 2022.
* Analysis of the impact of key events as well the drivers and restraints affecting the Japan seasonal influenza market.

Reasons to buy

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of drug performance
* Obtain sales forecast for drugs from 2012 to 2022 in Japan

Partial Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis
4 Disease Management
4.1 Influenza Vaccination Policy
4.2 Japan
4.2.1 Influenza Vaccination Recommendations and Policies
4.2.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Opportunity and Unmet Need
6.1 Overview
6.2 Unmet Needs
6.2.1 Higher level of patient awareness
6.2.2 Increased efficacy in the elderly and young children (<2 years old)
6.2.3 Improved vaccine side-effect profiles
6.2.4 More efficient vaccine manufacturing process
6.2.5 More cost-effective vaccines
6.3 Gap Analysis
6.4 Opportunities
6.4.1 Expanded breadth of protection against viral strains
6.4.2 Increased duration of protection
6.4.3 T-cell involvement
7 Pipeline Assessment
7.1 Overview
7.2 Promising vaccines in clinical development
7.2.1 ASP7374 (UMN-0502)
8 Market Outlook
8.1 Japan
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Vaccine Coverage
9.4.2 Vaccines Included
9.4.3 Key Launch Dates
9.4.4 Influenza Vaccine Tender System Assumptions
9.4.5 General Pricing Assumptions
9.4.6 Individual Vaccine Assumptions
9.4.7 Pricing of Pipeline Agents
9.5 Physicians and Specialists Included in this Study
9.6 Primary Research - Prescriber Survey
9.7 About the Authors
9.7.1 Authors
9.7.2 Global Head of Healthcare
9.8 About GlobalData
9.9 Contact Us
9.10 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Notable Influenza Pandemics
Table 2: Symptoms of Influenza
Table 3: Influenza Vaccination Recommendation Committees by Country
Table 4: Leading Influenza Vaccines, 2012
Table 5: Overall Unmet Needs - Current Level of Attainment
Table 6: Clinical Unmet Needs - Gap Analysis, 2012
Table 7: Seasonal Influenza Vaccines - Phase Pipeline, 2012
Table 8: Product Profile - ASP7374 (UMN-0502)

Full Table of Contents is available at:

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Bill Thompson
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact